Certain cardiovascular patient groups should only use Nicorette Invisi Transdermal Patch after consulting a physician. These patients include those who have experienced a serious cardiovascular event, or hospitalization for a cardiovascular complaint, in the previous 4 weeks (eg, stroke, myocardial infarction, unstable angina, cardiac arrhythmia, coronary artery bypass graft and angioplasty) or those who suffer from uncontrolled hypertension.
Nicorette Invisi Transdermal Patch should be used with caution in patients with severe/moderate hepatic impairment, severe renal impairment, active duodenal and gastric ulcers. The risk of using nicotine replacement therapy should be weighed against the risk of continued smoking.
Nicotine, both from nicotine replacement products and smoking, causes the release of catecholamines from the adrenal medulla. Therefore, Nicorette Invisi Transdermal Patch should also be used with caution in patients with uncontrolled hyperthyroidism or pheochromocytoma.
Patients with diabetes mellitus may require lower doses of insulin as a result of smoking cessation.
Nicorette Invisi Transdermal Patch should be removed prior to undergoing any Magnetic Resonance Imaging (MRI) procedures to prevent the risk of burns.